A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis

Arthritis Research and Therapy

Volumn 11, Issue 6, 2009, Pages

  Le Goff, Benoit ^a,b,c   Soltner, Elise ^a,b,c   Charrier, Céline ^a,b   Maugars, Yves ^c   Rédini, Françoise ^a,b   Heymann, Dominique ^a,b,c   Berthelot, Jean Marie ^a,b,c  

^a Universite de Nantes   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; METHOTREXATE; ZOLEDRONIC ACID; ANTIRHEUMATIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE EROSION; BONE MASS; COLLAGEN INDUCED ARTHRITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MONONUCLEAR CELL; MORPHOMETRICS; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; RADIOGRAPHY; RAT; SCORING SYSTEM; SPRAGUE DAWLEY RAT; STAINING; THICKNESS; TIBIA; ANIMAL; BONE; COMPUTER ASSISTED TOMOGRAPHY; DRUG COMBINATION; PATHOLOGY; PHOTON ABSORPTIOMETRY; RHEUMATOID ARTHRITIS;

ABSORPTIOMETRY, PHOTON; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE AND BONES; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; METHOTREXATE; OSTEOCLASTS; RATS; RATS, SPRAGUE-DAWLEY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77952538875     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2877     Document Type: Article

References (40)

1. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002, 110:1419-1427. 151809, 12438440.
2. Schett G. Erosive arthritis. Arthritis Res Ther 2007, 9(Suppl 1):S2. 1924517, 17634141, 10.1186/ar2166.
3. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998, 152:943-951. 1858257, 9546355.
4. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, Benoist C, Gravallese EM. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001, 159:1689-1699. 1867076, 11696430.
5. Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, Dunstan CR, Martin TJ, Gillespie MT. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002, 161:1419-1427. 1867274, 12368214.
6. Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:1068-1076. 10.1093/rheumatology/kel045, 16490750.
7. Rivollier A, Mazzorana M, Tebib J, Piperno M, Aitsiselmi T, Rabourdin-Combe C, Jurdic P, Servet-Delprat C. Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 2004, 104:4029-4037. 10.1182/blood-2004-01-0041, 15308576.
8. Romas E. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates. Best Pract Res Clin Rheumatol 2005, 19:1065-1079. 10.1016/j.berh.2005.06.008, 16301197.
9. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, Heijde D, Zhou L, Tsuji W, Newmark R, . Denosumab Rheumatoid Arthritis Study Group Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008, 58:1299-1309. 10.1002/art.23417, 18438830, Denosumab Rheumatoid Arthritis Study Group.
10. Heymann D, Ory B, Gouin F, Green JR, Rédini F. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med 2004, 10:337-343. 10.1016/j.molmed.2004.05.007, 15242682.
11. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN, . HORIZON investigators Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009, 373:1253-1263. 10.1016/S0140-6736(09)60250-6, 19362675, HORIZON investigators.
12. Herrak P, Görtz B, Hayer S, Redlich K, Reiter E, Gasser J, Bergmeister H, Kollias G, Smolen JS, Schett G. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 2004, 50:2327-2337. 10.1002/art.20384, 15248234.
13. Sims NA, Green JR, Glatt M, Schlict S, Martin TJ, Gillespie MT, Romas E. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 2004, 50:2338-2346. 10.1002/art.20382, 15248235.
14. Jarrett SJ, Conaghan PG, Sloan VS, Papanastasiou P, Ortmann CE, O'Connor PJ, Grainger AJ, Emery P. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 2006, 54:1410-1414. 10.1002/art.21824, 16645968.
15. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999, 159:2542-2550. 10.1001/archinte.159.21.2542, 10573044.
16. Finckh A, Simard JF, Duryea J, Liang MH, Huang J, Daneel S, Forster A, Gabay C, Guerne PA. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. Arthritis Rheum 2006, 54:54-59. 10.1002/art.21491, 16385495.
17. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593. 10.1056/NEJM200011303432201, 11096165.
18. Lee CK, Lee EY, Chung SM, Mun SH, Yoo B, Moon HB. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum 2004, 50:3831-3843. 10.1002/art.20637, 15593184.
19. Fan C, Cool JC, Scherer MA, Foster BK, Shandala T, Tapp H, Xian CJ. Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment. Bone 2009, 44:61-70. 10.1016/j.bone.2008.09.014, 18976724.
20. Morgan SL, Baggott JE, Bernreuter WK, Gay RE, Arani R, Alarcón GS. MTX affects inflammation and tissue destruction differently in the rat AA model. J Rheumatol 2001, 28:1476-1481.
21. Esser RE, Hildebrand AR, Angelo RA, Watts LM, Murphey MD, Baugh LE. Measurement of radiographic changes in adjuvant-induced arthritis in rats by quantitative image analysis. Arthritis Rheum 1995, 38:129-138. 10.1002/art.1780380120, 7818562.
22. Sancho D, Gómez M, Viedma F, Esplugues E, Gordón-Alonso M, García-López MA, de la Fuente H, Martínez-A C, Lauzurica P, Sánchez-Madrid F. CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis. J Clin Invest 2003, 112:872-882. 193672, 12975472.
23. Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Valkema R, Westedt ML, Landman JO, Pauwels EK, Breedveld FC. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 1996, 39:396-402. 10.1002/art.1780390307, 8607888.
24. Maccagno A, Di Giorgio E, Roldan EJ, Caballero LE, Perez Lloret A. Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scand J Rheumatol 1994, 23:211-214. 10.3109/03009749409103063, 8091148.
25. Valleala H, Laasonen L, Koivula MK, Mandelin J, Friman C, Risteli J, Konttinen YT. Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol 2003, 30:468-473.
26. Gasser JA, Ingold P, Venturiere A, Shen V, Green JR. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 2008, 23:544-551. 10.1359/jbmr.071207, 18072878.
27. Harada H, Nakayama T, Nanaka T, Katsumata T. Effects of bisphosphonates on joint damage and bone loss in rat adjuvant-induced arthritis. Inflamm Res 2004, 53:45-52. 10.1007/s00011-003-1214-4, 15021968.
28. Yoshida M, Kanno Y, Ishisaki A, Tokuda H, Hirade K, Nakajima K, Katagiri Y, Shimizu K, Kozawa O. Methotrexate suppresses inflammatory agonist induced interleukin 6 synthesis in osteoblasts. J Rheumatol 2005, 32:787-795.
29. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002, 4:266-273. 128935, 12106498, 10.1186/ar419.
30. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005, 57:163-172. 10.1124/pr.57.2.3, 15914465.
31. Suzuki Y, Nakagawa M, Masuda C, Ide M, Uehara R, Ichikawa Y, Mizushima Y. Short-term low dose methotrexate ameliorates abnormal bone metabolism and bone loss in adjuvant induced arthritis. J Rheumatol 1997, 24:1890-1895.
32. Ragab AH, Frech RS, Vietti TJ. Osteoporotic fractures secondary to methotrexate therapy of acute leukaemia in remission. Cancer 1970, 25:580-585. 10.1002/1097-0142(197003)25:3<580::AID-CNCR2820250313>3.0.CO;2-M, 5264439.
33. May KP, West SG, McDermott MT, Huffer WE. The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum 1994, 37:201-206. 10.1002/art.1780370208, 8129775.
34. Wheeler DL, Griend RA, Wronski TJ, Miller GJ, Keith EE, Graves JE. The short- and long-term effects of methotrexate on the rat skeleton. Bone 1995, 16:215-221. 10.1016/8756-3282(94)00032-U, 7756050.
35. Schwartz AM, Leonidas JC. Methotrexate osteopathy. Skeletal Radiol 1984, 11:13-16. 10.1007/BF00361126, 6424236.
36. di Munno O, Mazzantini M, Sinigaglia L, Bianchi G, Minisola G, Muratore M, la Corte R, di Matteo L, Canesi B, Caminiti M, Broggini M, Adami S. Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol 2004, 31:1305-1309.
37. Cranney AB, McKendry RJ, Wells GA, Ooi DS, Kanigsberg ND, Kraag GR, Smith CD. The effect of low dose methotrexate on bone density. J Rheumatol 2001, 28:2395-2399.
38. Minaur NJ, Kounali D, Vedi S, Compston JE, Beresford JN, Bhalla AK. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology (Oxford) 2002, 41:741-749. 10.1093/rheumatology/41.7.741, 12096222.
39. Spadaro JA, Damron TA, Horton JA, Margulies BS, Murray GM, Clemente DA, Strauss JA. Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge. J Orthop Res 2006, 24:936-944. 10.1002/jor.20145, 16609966.
40. Yilmaz L, Ozoran K, Gündüz OH, Uçan H, Yücel M. Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol Int 2001, 20:65-69. 10.1007/s002960000080, 11269535.